Biosensors & Bioelectronics

Biography

Biography: Mandana Veiseh

Abstract

Recent decades have witnessed many advances in development of cell-based biosensors (CBBs) for addressing clinical, environmental and toxicological problems. While some could be useful means for diagnosis, prognosis and treatments of lethal diseases such as metastatic cancers or for precision medicine, far too many have not translated into on-site use. Contributing reasons are sensitivity of cells to micro- and nano-environmental alterations that result in noise and distortion from optimum condition, lower specificity of cell-based- compared to nucleic-acid- or antibody-based sensors, and longevity concerns. These CBBs and their integrated bioelectronics, if devised and targeted to address the noted shortcomings, are capable of providing comprehensive functional information and insights into the mechanisms of actions upon cellular interaction with bioactive stimuli (such as bioprobes, drugs, and environmental challenges) or during expression of useful biomarkers. The complexity, heterogeneity, and multi-parameter nature of these processes require development of high-performance and field-ready technologies suitable for handling and analyzing large numbers of heterogeneous samples and providing quantitative__ideally digitized, predictive, and integrated readouts from living cells. This talk presents technologies that have advanced our understanding, including multi-omics, imaging, and label-specific chemical assays, followed by some examples of missing links for proper tackling of aggressive disease states regardless of the culprits. In end, the promise of polysensing technologies for capturing multiplexed biomarkers and temporal/spatial correlations that would otherwise be missed by static and label-specific measurements on fixed cells or summing of single mode biomarkers sensed by separate equipment or at different times will be discussed.